Huntington Disease: Comprehensive Disease Characteristics Report

Executive Summary

Huntington Disease (HD) is a devastating, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion (≥36 repeats; full penetrance ≥40) in exon 1 of the huntingtin gene (HTT) on chromosome 4p16.3. The expanded polyglutamine tract in the huntingtin protein — a 3,144 amino acid multifunctional scaffold essential for vesicular transport, transcription, autophagy, and neuronal survival — causes misfolding, aggregation, and toxic gain-of-function, preferentially destroying GABAergic medium spiny neurons (MSNs) in the striatum through eight converging pathogenic mechanisms. HD manifests as a clinical triad of progressive motor dysfunction (chorea evolving to rigidity), cognitive decline progressing to dementia, and psychiatric disturbances, with detectable premanifest changes beginning 15-20 years before motor onset. With a prevalence of approximately 5-7 per 100,000 in Western populations (~30,000 affected in the US), HD remains without disease-modifying therapy, though three VMAT2 inhibitors provide symptomatic chorea relief. The therapeutic landscape is undergoing a paradigm shift following the tominersen trial failure, with the most promising emerging strategies being somatic CAG expansion inhibitors (targeting MSH3/FAN1), allele-selective HTT lowering, and AAV-mediated gene therapy, supported by HD's uniquely organized global research infrastructure.

This report covers 21 sections: genetics, disease identifiers, epidemiology, huntingtin protein biology, molecular pathogenesis, neuropathology, clinical features, premanifest phase, differential diagnosis, diagnosis, current treatment, therapeutic pipeline, animal models, emerging concepts, genetic counseling, psychosocial impact, intermediate alleles, treatment comparison, clinical trial lessons, research infrastructure, and future directions.

1. Genetic Basis

1.1 The HTT Gene and CAG Repeat Expansion

• Gene: HTT (Huntingtin), located on chromosome 4p16.3
• Mutation: Expansion of a polymorphic CAG trinucleotide repeat in exon 1
• Protein product: Huntingtin (HTT), a large ~348 kDa scaffolding protein with roles in vesicular transport, transcriptional regulation, and cell survival
• Inheritance: Autosomal dominant with complete penetrance at ≥40 CAG repeats

1.2 CAG Repeat Length Categories

1.3 CAG Length and Age of Onset

The CAG repeat length is inversely correlated with age of motor onset and accounts for approximately 50–70% of the variance in onset age. However, the remaining variance is influenced by:

• Genetic modifiers: DNA mismatch repair genes (MSH3, FAN1, MLH1, PMS1, PMS2, LIG1)
• Somatic CAG expansion: Progressive lengthening of the CAG repeat in somatic cells, particularly in striatal neurons
• Environmental factors: Exercise, cognitive reserve, and other lifestyle factors (less well-characterized)

1.4 Anticipation

HD shows genetic anticipation, particularly with paternal transmission. The CAG repeat is unstable during spermatogenesis, leading to potential intergenerational expansions. This explains why juvenile HD cases are more commonly paternally inherited.

2. Disease Identifiers

3. Epidemiology

3.1 Prevalence

• Global estimate: ~2.7 per 100,000 overall
• United States: ~30,000 affected individuals; ~200,000 at risk
• Trend: Prevalence appears to be increasing in Western countries due to improved diagnosis, genetic testing, longer survival with supportive care, and new mutations from intermediate alleles

3.2 Incidence

• Approximately 0.4–0.5 per 100,000 per year in Western populations
• Higher in populations with European ancestry

3.3 Population Variation

The marked ethnic/geographic variation in prevalence correlates with the distribution of intermediate and high-normal CAG alleles. Western European populations have a higher proportion of alleles near the pathogenic threshold, providing a reservoir for new mutations through intergenerational expansion.

4. Huntingtin Protein Biology

4.1 Protein Structure

Huntingtin is a large (3,144 amino acids, ~348 kDa) scaffold protein containing: - Polyglutamine (polyQ) tract: Encoded by the CAG repeat in exon 1; normally 6-26 Qs - Proline-rich domain (PRD): Adjacent to polyQ; modulates aggregation propensity - HEAT repeats: Four clusters of α-helical repeat domains forming a solenoid structure; mediate protein-protein interactions - Subcellular localization: Nucleus, cytoplasm, axons, dendrites, perikaryon, and associated with vesicles and organelles

4.2 Normal Functions of Wild-Type Huntingtin

4.3 Key Post-Translational Modifications

Key Insight: The finding that S421 phosphorylation is naturally lowest in striatal neurons provides a molecular explanation for selective vulnerability — these neurons have the least protective modification of HTT, making them most susceptible to mHTT toxicity.

4.4 Signaling Pathways Involving HTT

Wikidata pathway analysis reveals HTT participates in multiple critical signaling cascades: MAPK, Wnt, insulin, TGF-beta, VEGF, apoptosis, PDGF, p38 MAPK, ErbB, toll-like receptor, and inflammatory (IL-1, IL-6, TNF-alpha) pathways. This broad involvement explains why mHTT disruption has such pleiotropic effects.

5. Molecular Pathogenesis

5.1 Mutant Huntingtin Protein (mHTT) Toxicity

The expanded polyglutamine (polyQ) tract causes huntingtin to: 1. Misfold and aggregate → forms intranuclear inclusions and cytoplasmic aggregates 2. Sequester essential proteins → disrupts proteostasis, transcription, and transport 3. Undergo aberrant proteolytic cleavage → generates toxic N-terminal fragments

5.2 Key Pathogenic Mechanisms

1. Protein aggregation and proteostasis failure: mHTT overwhelms the ubiquitin-proteasome system and autophagy pathways
2. Transcriptional dysregulation: mHTT interacts with and sequesters transcription factors (CBP, Sp1, TFIID, REST/NRSF), leading to widespread gene expression changes, including downregulation of BDNF and PGC-1α
3. Mitochondrial dysfunction: Impaired Complex II/III activity, reduced ATP production, increased oxidative stress, defective mitochondrial dynamics (fission/fusion)
4. Excitotoxicity: Enhanced sensitivity of MSNs to glutamate via NMDA receptors, leading to calcium overload and cell death
5. BDNF depletion: mHTT impairs BDNF transcription in cortical neurons and disrupts vesicular transport of BDNF along the corticostriatal pathway
6. Somatic CAG repeat expansion: DNA mismatch repair (MMR) machinery drives progressive lengthening of the CAG repeat in post-mitotic neurons, particularly in the striatum; this is now recognized as a critical determinant of disease onset
7. Synaptic dysfunction: Altered neurotransmitter release, impaired synaptic plasticity, and progressive corticostriatal circuit disruption
8. Neuroinflammation: Microglial activation, reactive astrocytosis, and elevated inflammatory cytokines (IL-6, IL-8, TNF-α) in both CNS and periphery

5.3 Selective Neuronal Vulnerability

Medium spiny neurons (MSNs) in the caudate nucleus and putamen are preferentially affected due to: - High excitatory glutamatergic input from cortex - Dependence on BDNF from cortical projections - High metabolic demand and vulnerability to energy deficits - Greater somatic CAG expansion in striatal vs. other brain regions - Expression pattern of DNA repair enzymes promoting instability

The indirect pathway MSNs (D2 receptor-expressing, enkephalin-positive) are affected earliest, followed by direct pathway MSNs (D1 receptor-expressing, substance P-positive), correlating with the clinical progression from chorea to rigidity.

6. Neuropathology

6.1 Vonsattel Grading System

6.2 Brain Regions Affected (in order of severity)

1. Caudate nucleus (earliest and most severe)
2. Putamen
3. Globus pallidus
4. Cerebral cortex (layers III, V, VI)
5. Thalamus, subthalamic nucleus
6. Hippocampus, cerebellum (later stages)

7. Clinical Features

7.1 The Clinical Triad

Motor Symptoms

• Chorea (most characteristic): Involuntary, irregular, non-repetitive movements
• Dystonia: Sustained abnormal postures, increases as disease progresses
• Bradykinesia/rigidity: Increasingly prominent in later stages
• Gait disturbance: Wide-based, unsteady gait; falls are common
• Oculomotor abnormalities: Saccade initiation difficulties (often earliest motor sign)
• Dysphagia: Swallowing difficulty; aspiration pneumonia is a leading cause of death
• Dysarthria: Progressive speech deterioration

Cognitive Symptoms

• Executive dysfunction: Impaired planning, mental flexibility, multitasking (earliest cognitive change)
• Psychomotor slowing: Reduced processing speed
• Visuospatial deficits
• Memory impairment: Primarily retrieval-based (vs. encoding-based in Alzheimer's)
• Progressive dementia: Inevitable in later stages; subcortical pattern
• Cognitive changes may precede motor onset by 10-15 years

Psychiatric Symptoms (often precede motor onset)

• Depression: 33–69% of patients; suicide risk elevated 5-10x
• Irritability/aggression: Common and distressing for families
• Anxiety: 34–61% of patients
• Apathy: Increases with disease progression; distinct from depression
• Obsessive-compulsive behaviors: 10–52%
• Psychosis: Relatively rare (<10%)
• Disinhibition and impulsivity

7.2 Other Clinical Features

• Weight loss: Progressive, multifactorial (increased energy expenditure, dysphagia, hypothalamic dysfunction)
• Sleep disturbances: Circadian rhythm disruption, insomnia, increased sleep latency (prevalence systematically studied; PMID: 41722529)
• Autonomic dysfunction: Bowel/bladder issues
• Peripheral manifestations: Skeletal muscle wasting, cardiac dysfunction, immune dysregulation

7.3 Disease Stages (Shoulson-Fahn Total Functional Capacity)

Mean age of motor onset: ~45 years (range: childhood to >70 years) Mean disease duration: 15–20 years from motor onset to death Cause of death: Most commonly aspiration pneumonia, followed by cardiovascular disease and suicide

7.4 Juvenile Huntington Disease (JHD)

• Onset before age 20 (approximately 5-10% of cases)
• More commonly paternally inherited (CAG expansion during spermatogenesis)
• Phenotype differs from adult-onset: rigidity and bradykinesia predominate (vs. chorea)
• Additional features: seizures (25-40%), rapid cognitive decline, cerebellar ataxia
• Faster progression; mean duration ~8-10 years

8. The Premanifest Phase: A Window for Intervention

HD is unique among neurodegenerative diseases in that gene-positive individuals can be identified decades before clinical onset, enabling detailed characterization of the premanifest phase.

8.1 Timeline of Premanifest Changes

8.2 Key Observational Studies

• PREDICT-HD: Demonstrated that cognitive and brain imaging changes are detectable up to 15+ years before motor diagnosis
• TRACK-HD/TRACK-ON: Longitudinal study showing progressive striatal atrophy, white matter changes, and cognitive decline in premanifest carriers
• ENROLL-HD: World's largest observational study of HD families (>20,000 participants); provides natural history data and machine-learning progression models (PMID: 34870344)

8.3 Therapeutic Implications

The extended premanifest phase, combined with genetic predictability and measurable biomarkers (NfL, volumetric MRI), makes HD uniquely suited for preventive clinical trials. Intervening before irreversible neuronal loss could maximize therapeutic benefit. Current trials (e.g., HD-DCI) are enrolling premanifest carriers based on biomarker-predicted proximity to onset.

9. Differential Diagnosis

9.1 Genetic HD Phenocopies (HTT-Negative)

Approximately 2-40% of patients presenting with an HD-like phenotype test negative for HTT CAG expansion (PMID: 41612618). Key phenocopies include:

9.2 Acquired Causes of Chorea

9.3 Diagnostic Algorithm

For patients presenting with chorea ± cognitive/psychiatric features: 1. First-line: HTT CAG repeat testing (definitive for HD) 2. If HTT-negative: Blood smear (acanthocytes), ceruloplasmin/copper (Wilson), thyroid function, ANA/antiphospholipid antibodies 3. If still undiagnosed: Gene panel for HD phenocopies (JPH3, TBP, ATN1, C9orf72, PRNP, VPS13A, XK, NKX2-1) 4. Consider: Brain MRI (caudate atrophy pattern), anti-neuronal antibodies

10. Diagnosis

10.1 Clinical Diagnosis

• Based on unequivocal motor signs (chorea or other movement disorder) in the setting of a positive family history
• Unified Huntington Disease Rating Scale (UHDRS) for standardized assessment
• Diagnostic Confidence Level (DCL) of 4 = motor abnormalities unequivocal and characteristic of HD

10.2 Genetic Testing

• Diagnostic testing: PCR-based CAG repeat sizing from blood DNA; ≥36 CAGs confirms genetic diagnosis
• Predictive testing: Available for at-risk individuals (50% risk if one parent affected); requires genetic counseling per international guidelines
• Prenatal testing: Available via chorionic villus sampling or amniocentesis
• Preimplantation genetic testing (PGT): Option for IVF to select unaffected embryos

10.3 Neuroimaging

• MRI: Caudate nucleus atrophy (progressive loss of caudate head convexity); measurable years before motor onset
• Volumetric MRI: Quantitative striatal volume loss is a sensitive progression biomarker
• PET/SPECT: Reduced D2 receptor binding in striatum; reduced glucose metabolism
• MR spectroscopy: Altered metabolite profiles (reduced NAA, elevated myo-inositol) in striatum

10.4 Fluid Biomarkers

11. Current Treatment

11.1 Approved Symptomatic Therapies

11.2 Off-Label and Supportive Treatments

• Antipsychotics (olanzapine, risperidone): For chorea, psychosis, aggression
• Antidepressants (SSRIs, SNRIs): For depression and anxiety
• Benzodiazepines: For anxiety and myoclonus
• Physical therapy: Gait training, fall prevention, exercise programs
• Speech therapy: For dysarthria and dysphagia management
• Occupational therapy: Adaptive strategies for daily living
• Nutritional support: High-calorie diets; PEG tube in advanced stages
• Palliative care: Increasingly important in advanced disease

11.3 No Disease-Modifying Therapy Is Currently Approved

12. Therapeutic Pipeline and Emerging Strategies

12.1 HTT-Lowering Approaches

12.2 Somatic Expansion Inhibitors (Novel Paradigm)

• Target: MSH3 (MutSβ complex) — the DNA mismatch repair component that drives somatic CAG expansion
• Rationale: GWAS modifier studies show MSH3 variants alter onset age; reducing MSH3 could slow somatic expansion
• Status: Multiple preclinical programs; considered the most promising emerging therapeutic approach
• FAN1 activation: FAN1 nuclease protects against somatic expansion; activation strategies in development

12.3 Other Approaches

• CRISPR gene editing: Direct correction of expanded CAG repeats (preclinical)
• Immunotherapy: Targeting extracellular mHTT aggregates
• Neuroprotection: BDNF supplementation, mitochondrial enhancers (CoQ10 trials negative)
• Cell replacement therapy: iPSC-derived MSN transplantation (very early stage)

13. Animal Models

14. Key Emerging Concepts

14.1 HD as a Developmental Disorder

Recent evidence suggests mHTT affects brain development, with subtle abnormalities in cortical and striatal organization present from early life, years before clinical onset (PMID: 41252373). This challenges the traditional view of HD as purely a late-onset neurodegenerative disease.

14.2 Somatic Instability as the Central Disease Driver

The recognition that somatic CAG expansion in striatal neurons may be the rate-limiting step in disease onset has fundamentally shifted the therapeutic paradigm. The inherited CAG length sets the stage, but it is the ongoing somatic expansion that ultimately triggers neuronal death.

14.3 Peripheral Pathology

HD is increasingly recognized as a systemic disease, with pathology in skeletal muscle, heart, immune system, and endocrine organs, challenging the CNS-centric view.

14.4 Biomarker-Driven Clinical Trials

NfL in plasma has emerged as a powerful, minimally invasive biomarker that can detect disease-related changes in premanifest HD carriers and may serve as a surrogate endpoint in clinical trials.

15. Genetic Counseling and Predictive Testing

15.1 Predictive Testing Framework

• Eligibility: At-risk individuals (typically ≥18 years) with a first-degree relative with confirmed HD
• Uptake: Only ~5-20% of at-risk individuals choose predictive testing
• International guidelines (HDSA/IHA/WFN) require pre- and post-test genetic counseling
• Protocol: Minimum two counseling sessions; psychological assessment; neurological exam; waiting period between sessions; post-result follow-up
• "Right not to know": Must be respected; testing of minors is generally discouraged unless medically indicated

15.2 Reproductive Options

15.3 Ethical and Legal Considerations

• Genetic Information Nondiscrimination Act (GINA, US): Protects against discrimination in health insurance and employment based on genetic information, but does NOT cover life, disability, or long-term care insurance
• Duty to warn: Genetic counselors face ethical tensions between patient confidentiality and potential duty to inform at-risk relatives
• Incidental findings: Expanded testing panels may reveal HD risk incidentally
• Psychological impact of results: Both positive AND negative results can cause psychological distress (survivor guilt, altered family dynamics)

16. Psychosocial Impact and Family Burden

16.1 Impact on Patients

• Suicide: Risk 5-10x general population; highest around time of diagnosis and in early-mid stages when awareness is preserved
• Depression: Affects 33-69% of patients; both reactive and neurobiological components
• Employment: Progressive inability to work; mean retirement ~5-8 years after motor onset
• Driving cessation: Usually required within first few years of motor onset
• Decision-making capacity: Progressively impaired; advance care planning essential early

16.2 Impact on Families and Caregivers

• Caregiver burden: Averages 40-70 hours/week in advanced stages (PMID: 26688844)
• Multi-generational impact: Children witness parent's decline while potentially carrying the gene
• Relationship strain: Behavioral changes (apathy, irritability, disinhibition) challenge partnerships
• Financial impact: Estimated $50,000-$100,000+/year in advanced stages (US); loss of income compounds costs
• Caregiver health: Elevated rates of depression, anxiety, and physical health problems

16.3 Support Resources

• Huntington's Disease Society of America (HDSA): Centers of Excellence, support groups, social services
• European Huntington's Disease Network (EHDN): Research and care coordination
• HD Youth Organization (HDYO): Resources specifically for young people impacted by HD
• ENROLL-HD: Global observational study providing community and research connection

17. Intermediate Alleles and New Mutations

17.1 Population Genetics of Intermediate Alleles

• ~2-7% of the general population carries intermediate alleles (27-35 CAGs)
• Prevalence varies by ethnicity, highest in Western European populations
• Meiotically unstable, especially during spermatogenesis (paternal transmission)
• ~6-10% chance of expansion into disease range per paternal transmission
• Alleles at 33-35 CAGs carry the highest expansion risk

17.2 Clinical Significance

• Intermediate allele carriers themselves do NOT develop HD
• However, a scoping review (PMID: 41406155) found some evidence of subtle phenotypic features in carriers:
• Possible mild cognitive or psychiatric symptoms
• Subtle motor signs in some individuals
• Clinical significance remains debated; most carriers are fully asymptomatic
• Accounts for ~1-3% of HD cases presenting without family history ("sporadic" or "de novo" HD)

17.3 Evolutionary Implications

Intermediate alleles represent a mutation-selection balance: new mutations continuously arise from the intermediate allele pool, maintaining HD in the population despite the reduced reproductive fitness of affected individuals. This also explains why HD prevalence is higher in populations (Western European) with larger proportions of high-normal/intermediate alleles.

18. VMAT2 Inhibitor Treatment Comparison

Based on a Bayesian network meta-analysis (PMID: 41069601):

Clinical Pearl: All three VMAT2 inhibitors are symptomatic only (reduce chorea severity); none modify disease progression. Treatment choice should be individualized based on patient comorbidities, polypharmacy, and tolerance.

19. Lessons from Clinical Trials

19.1 The Tominersen Pivotal Moment

The Phase III GENERATION-HD1 trial of tominersen (Roche/Ionis) — a non-selective antisense oligonucleotide targeting both mutant and wild-type HTT via intrathecal delivery — was halted in March 2021 after an independent monitoring committee found that higher doses worsened clinical outcomes compared to placebo. Key lessons:

1. Non-selective HTT lowering is risky: Wild-type HTT has essential functions; reducing it below a critical threshold may cause harm
2. Neuroinflammation from intrathecal delivery: The procedure and drug itself may trigger CNS inflammation independent of target engagement
3. Dose-response is not linear: Higher doses ≠ better outcomes; there may be a narrow therapeutic window
4. Patient stratification matters: Younger patients with lower disease burden may respond differently than advanced patients
5. Biomarker dissociation: mHTT lowering in CSF did not translate to clinical benefit, questioning CSF mHTT as a surrogate endpoint

19.2 Reshaping the Therapeutic Paradigm

Post-tominersen, the field has shifted toward: - Allele-selective ASOs (WVE-003): Target mHTT-linked SNPs to lower only mutant HTT, preserving wild-type function - One-time gene therapy (AMT-130): AAV-delivered miRNA for sustained local HTT lowering in the striatum - Oral small molecules (PTC518): Splice modulators offering non-invasive, titratable dosing - Somatic expansion inhibitors: An entirely different approach that doesn't require HTT protein lowering — targets the upstream DNA instability mechanism - Combination strategies: Multiple complementary mechanisms may ultimately be needed

19.3 Clinical Trial Design Evolution

• Composite endpoints (combining motor, cognitive, and functional measures) now preferred over single-domain endpoints
• Enrichment designs using biomarker-defined populations (e.g., NfL-stratified)
• Longer trial durations to capture disease-modifying effects vs. symptomatic changes
• Adaptive platform designs allowing multiple therapies to be tested simultaneously
• Digital and remote assessments to reduce patient burden and increase data granularity

20. Research Infrastructure and Community

20.1 Major Research Platforms

20.2 Why HD is Uniquely Positioned for Breakthroughs

HD occupies a uniquely favorable position among neurodegenerative diseases for therapeutic development:

1. Genetic clarity: Single-gene cause with 100% penetrance at ≥40 CAGs — no diagnostic ambiguity
2. Predictable trajectory: CAG-based onset prediction enables premanifest intervention
3. Measurable biomarkers: NfL, mHTT, volumetric MRI provide quantitative tracking
4. Organized community: Global patient registries, advocacy organizations, and research networks
5. Paradigm disease: Insights benefit all 45+ trinucleotide repeat disorders and neurodegeneration broadly
6. Animal models: Well-characterized transgenic and knock-in models spanning mice to large animals

21. Limitations and Future Directions

21.1 Limitations of This Report

• Prevalence estimates vary across studies and meta-analyses; some regional data may be outdated
• The therapeutic pipeline is rapidly evolving; clinical trial statuses change frequently
• Mechanistic understanding continues to evolve, particularly regarding the relative contributions of gain-of-function vs. loss-of-function
• Psychosocial burden estimates are based primarily on Western healthcare systems
• This report relies on published literature and database queries; unpublished clinical trial data may alter some conclusions

21.2 Key Unanswered Questions

1. Why are striatal MSNs selectively vulnerable despite ubiquitous HTT expression? (Partial answers: S421-P levels, somatic expansion rates, BDNF dependence — but full picture remains unclear)
2. What somatic CAG expansion threshold triggers neuronal death? This critical question could define therapeutic targets
3. Can allele-selective HTT lowering avoid tominersen's toxicity while preserving efficacy?
4. Is there an optimal therapeutic window in the premanifest phase for disease modification?
5. What is the contribution of wild-type HTT loss-of-function to HD pathogenesis?
6. Can somatic expansion be therapeutically stopped or reversed in already-expanded neurons?
7. Do peripheral manifestations (muscle, heart, immune) require separate therapeutic attention?
8. Can digital biomarkers provide more sensitive and continuous outcome measures than current clinical scales?

21.3 Future Directions

References (Selected Key Publications)

Genetics & Pathogenesis

1. Donaldson et al. (2026) "Huntington disease: somatic expansion, pathobiology and therapeutics." PMID: 41233526
2. Shin & Hefti (2025) "Huntington's as a developmental disorder." PMID: 41252373
3. Maiuri et al. (2021) "DNA Repair in HD: Somatic Instability and Alternative Hypotheses." PMID: 33579859
4. Warby et al. (2009) "Phosphorylation of huntingtin reduces accumulation of nuclear fragments." PMID: 18992820
5. Ehrnhoefer et al. (2011) "Posttranslational modifications and function of huntingtin." PMID: 21311053

Biomarkers & Natural History

1. Paulsen et al. (2025) "Systematic Review with Meta-Analysis of Biofluid Markers for HD." PMID: 41081429
2. Heim et al. (2025) "Serum NfL but not GFAP is a marker of early HD." PMID: 39891767
3. Rodrigues et al. (2020) "Mutant huntingtin and NfL have distinct longitudinal dynamics." PMID: 33328328
4. Wild et al. (2015) "Quantification of mHTT in CSF from HD patients." PMID: 25844897
5. Mohan et al. (2022) "Machine-Learning Derived HD Progression Model." PMID: 34870344

Therapeutics & Clinical Trials

1. Saade & Mestre (2024) "HD: Latest Frontiers in Therapeutics." PMID: 38861215
2. Winquist & Church (2025) "Inhibiting CAG repeat expansions as therapeutic strategy." PMID: 41130308
3. Huang et al. (2025) "VMAT2 inhibitors for HD chorea: network meta-analysis." PMID: 41069601
4. Giri et al. (2025) "Valbenazine Sprinkle formulation for dysphagia." PMID: 41215526
5. Rodrigues et al. (2025) "Cholinesterase inhibitors and memantine for HD cognition." PMID: 40791064

Clinical Features & Phenocopies

1. van Hofslot et al. (2026) "Clinical phenotype of intermediate allele carriers." PMID: 41406155
2. Cardoso et al. (2026) "Non-Huntington's disease chorea: expanding universe." PMID: 41612618
3. Schneider & Bird (2016) "HD, HD Look-Alikes, and Benign Hereditary Chorea." PMID: 30713928
4. Sneddon et al. (2026) "Sleep disturbances in HD and premanifest carriers." PMID: 41722529

Psychosocial & Epidemiology

1. van Walsem et al. (2022) "Quality of life, utilization, and costs in HD (Norway)." PMID: 36517848
2. Domaradzki (2015) "Impact of HD on Family Carers." PMID: 26688844

Emerging Science

1. Maimon (2026) "Huntington's disease is the best investment in neuroscience today." PMID: 41690900
2. Gavgani & García-Domínguez (2025) "Breakthroughs in AAV-Mediated Gene Therapy for HD." PMID: 41090742
3. Gulzar et al. (2026) "Therapeutic strategies for HD: current approaches and future." PMID: 40874597
4. Louessard et al. (2024) "HTT roles in striatal development and neuronal functions." PMID: 38427495

Report compiled: April 2026 | Based on 69+ literature sources, Wikidata SPARQL queries, and domain knowledge 13 confirmed findings recorded in knowledge graph across 5 iterations